Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Theratechnologies ( (TSE:TH) ) has shared an update.
Theratechnologies has announced an impending shortage of its product, EGRIFTA SV®, due to a voluntary shutdown of its manufacturing facility in 2024, with a shortage expected to affect patients by mid-January 2025. The company has filed a Prior Approval Supplement with the FDA and is awaiting responses to facilitate the release of new batches to pharmacies, emphasizing its commitment to affected patients and ongoing collaboration with the FDA to resolve the issue.
More about Theratechnologies
Theratechnologies Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. The company is actively involved in providing solutions, particularly with its FDA-approved product EGRIFTA SV®, which is used for specific medical conditions.
YTD Price Performance: 8.42%
Average Trading Volume: 93,451
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $92.11M
Find detailed analytics on TH stock on TipRanks’ Stock Analysis page.
